RepliCel to Present Clinical Trial Update at Stem Cell Meeting on the Mesa Partnering Forum in California
(firmenpresse) - VANCOUVER, BRITISH COLUMBIA -- (Marketwired) -- 10/02/14 -- RepliCel Life Sciences Inc. (TSX VENTURE: RP)(OTCQB: REPCF), a clinical stage regenerative medicine company focused on the development of autologous cell therapies will be presenting at the Stem Cell Meeting on the Mesa Partnering Forum on Tuesday, October 7, 2014 at 11:45 a.m. local time in La Jolla Ballroom 2 at the Estancia La Jolla Hotel.
The presentation by Mr. David Hall, CEO, will include an update on RepliCel's pending clinical trials for chronic Achilles tendinosis (RCT-A-01) and sun-damaged and aging skin (RCS-01) as well as its program for pattern hair loss (RCH-01). It will be webcast and posted on the conference website at , on RepliCel's website at http://www.replicel.com/investors/corporate-publications/ and on the Alliance for Regenerative Medicine website, after the event, at http://alliancerm.org/ bringing tremendous exposure to the company.
"The Stem Cell meeting does an excellent job of bring together leading researchers, clinical experts, senior executives, health care investors and top decision-makers in the regenerative medicine industry. With nearly 800 attendees from around the globe, it is a great environment for discussions around partnerships, collaborations and investment," commented David Hall, CEO of RepliCel.
Please visit for full information on the conference including registration. Complimentary attendance at this event is available for credentialed investors and members of the media only.
About RepliCel Life Sciences
RepliCel is a regenerative medicine company focused on developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function. The company's RCT-01, RCS-01 and RCH-01 cell therapies are designed to treat chronic tendinosis, damaged or aging skin, and pattern baldness. Shiseido Company, Limited has an exclusive license for RCH-01 in certain Asian countries including Japan, China and South Korea. All product candidates are based on RepliCel's innovative technology utilizing cell populations isolated from a patient's own healthy hair follicles. The company is also developing a propriety injection device optimized for the administration of its products and licensable for use with other dermatology applications. The company's product pipeline is comprised of multiple clinical trials all anticipated to launch in late 2014 in addition to Shiseido's own clinical trial of RCH-01 and the device in late prototype development. Visit for additional information.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contacts:
RepliCel Life Sciences Inc.
Tammey George
Director of Communications
604-248-8696
INVESTOR RELATIONS:
Christina Cameron
Investor Relations
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 02.10.2014 - 12:00 Uhr
Sprache: Deutsch
News-ID 340704
Anzahl Zeichen: 0
contact information:
Town:
VANCOUVER, BRITISH COLUMBIA
Kategorie:
Biotech
Diese Pressemitteilung wurde bisher 241 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"RepliCel to Present Clinical Trial Update at Stem Cell Meeting on the Mesa Partnering Forum in California"
steht unter der journalistisch-redaktionellen Verantwortung von
RepliCel Life Sciences Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
